Brainstorm Cell Therapeutics Received Written Agreement From FDA, Under Special Protocol Assessment, On Design For Phase 3B Trial Of NurOwn In Amyotrophic Lateral Sclerosis Expected To Start In 2024
Brainstorm Cell Therapeutics Received Written Agreement From FDA, Under Special Protocol Assessment, On Design For Phase 3B Trial Of NurOwn In Amyotrophic Lateral Sclerosis Expected To Start In 2024
根據特別協議評估，Brainstorm Cell Therapeutics收到了美國食品藥品管理局關於NuroWN在肌萎縮性側索硬化症中的3B期試驗的設計的書面協議，該試驗預計將於2024年開始
Brainstorm Cell Therapeutics Received Written Agreement From FDA, Under Special Protocol Assessment, On Design For Phase 3B Trial Of NurOwn In Amyotrophic Lateral Sclerosis Expected To Start In 2024
根據特別協議評估，Brainstorm Cell Therapeutics收到了美國食品藥品管理局關於NuroWN在肌萎縮性側索硬化症中的3B期試驗的設計的書面協議，該試驗預計將於2024年開始
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。